In a new Yale Cancer Center (YCC) study, researchers have demonstrated that a higher percentage of women with breast cancer had their disease diagnosed at an early stage in states with expanded Medicaid coverage through the Affordable Care Act (ACA). No...
The checkpoint inhibitor pembrolizumab (Keytruda) increases the survival time of patients with advanced head and neck cancers, according to a new global study led by Yale Cancer Center (YCC). The data was published today in the journal The Lancet.
The...
Patients who choose to receive alternative therapy as treatment for curable cancers instead of conventional cancer treatment have a higher risk of death, according to researchers from the Cancer Outcomes, Public Policy and Effectiveness Research (COPPER)...
According to the results of a large, global study led by Yale Cancer Center researchers, even a tiny amount of a biomarker known as PD-L1 (programmed death-ligand1) can predict a long-term survival benefit from using pembrolizumab (Keytruda). The drug is...
There are no approved treatment options for patients with advanced bladder cancer after they’ve received standard chemotherapy and immune treatments, but the results of a phase II clinical trial led by Yale Cancer Center and Smilow Cancer Hospital...
Racial disparities in timely cancer treatment disappeared in states that expanded Medicaid under the Affordable Care Act (ACA), according to an analysis of over 30,000 health records led by researchers at Yale Cancer Center. The findings were presented...